Log in or create an account for full access to this data.
Create a free account or log in to use this tool.
Create a free account or log in to explore DrugBank data.
Coagulation Factor IX Human is a coagulation factor used to treat hemophilia B or factor IX hemophilia. Factor IX (or Christmas factor) is one of the serine proteases of the coagulation system; it belongs to peptidase family S1.
- Mechanism
- Curator reviewed
Coagulation Factor IX is an important protein in the process of hemostasis and normal blood clotting as it plays a key role within the coagulation cascade. It is located within the blood plasma as a zymogen, an antecedent to enzymatic function, in its inactivated state. Factor IX is dependent on the presence of Vitamin K, and is activated to a serine protease by the function of Coagulation Factor XIa. Factor XIa cleaves the peptide bond associated with protein activation in Factor IX, leaving Factor IX with two exposed chains, a light chain and a heavy chain. These two chains are held together by several disulfide bonds that reinforce the structure of Factor IX's activated form. After being activated, Factor IX forms a complex with calcium ions, membrane phospholipids and Coagulation Factor VIII to activate Coagulation Factor X. The activation of Factor X then performs a similarly integral step in the blood coagulation cascade. The ultimate result of phenotypically normal coagulation factors is the creation of platelets for normal blood clotting.
- Primary indication
- Factor IX is used to treat Christmas disease.Curator reviewed · 3 structured indications
- Formula / weight
- C2041H3136N558O641S25 · 46548.2 Da
- First approval
- Canada, 2007 · United States, 1990
- Also known as
- Antihemophilic factor B · Coagulation factor IX (human) · Factor IX (Human) · Human coagulation factor IX
- Brand names
- Alphanine Sd
- Balfaxar
- Beriplex
- Immunine Vh
- Kcentra
- Octaplex
Resolves to
What you can answer from here — as of June 15, 2026
Which drugs share a target with Coagulation Factor IX Human, and which of those have an active Phase 3 trial?